Jesse Pierce alias Dr. Leaky Logic

Jesse Pierce is not licensed or approved by State Board of Naturopathic Medicine to diagnose, treat, or cure Bioidentical Hormone Replacement Therapy.

Bioidentical Hormone Replacement Therapy

Supports

The core idea of bioidentical menopausal hormone therapy is to use hormones structurally identical to endogenous estradiol (E2) and progesterone (P4), often delivered as estradiol plus micronized progesterone. High-quality randomized trials show that FDA‑approved oral bioidentical estradiol/progesterone combinations (such as TX‑001HR/Bijuva) are effective for relief of menopausal vasomotor symptoms, with breast and bleeding outcomes broadly similar to conventional hormone therapy over 12 months.^[15] These RCTs demonstrate adequate endometrial protection when 1 mg E2 is combined with 100 mg P4, with endometrial hyperplasia rates below 1%, meeting regulatory safety criteria.^[15] Systematic and randomized data on micronized progesterone show it can effectively oppose estrogen’s proliferative effects on the endometrium at appropriate doses, reducing glandular proliferation and protecting against hyperplasia.^[3][13][15] Narrative and guideline-level reviews indicate that approved bioidentical E2/P4 regimens provide standardized pharmacokinetics and a risk–benefit profile comparable to other estrogen–progestin therapies when used at evidence-based doses, and can be considered an effective option for symptomatic menopausal women.^[14][15]

Contradicts

The strongest contradictions apply not to regulated bioidentical products but to custom-compounded bioidentical hormone therapy as promoted by many influencers. Major professional guidance (e.g., ACOG) explicitly notes that evidence to support marketing claims of superior safety and effectiveness of compounded bioidentical menopausal hormone therapy is lacking and calls for high-quality randomized trials comparing custom‑compounded products with FDA‑approved hormone therapy.^[12] The 2022 position statement of the North American Menopause Society similarly highlights a dearth of safety and efficacy data and little or no robust pharmacokinetic evidence for compounded bioidentical hormone therapy, pointing out safety concerns including inconsistent dosing, impurities, lack of sterility, and absence of standardized risk labeling; it recommends compounded products only when women cannot tolerate any approved formulation or require a non‑available dose/formulation.^[16] A randomized pharmacokinetic trial comparing commonly used doses of compounded “Bi‑est” estrogen cream plus compounded progesterone with a standard estradiol patch plus micronized progesterone showed that compounded regimens produced substantially lower and more variable estradiol exposure than the patch, indicating that typical compounded doses may not be bioequivalent and that assumptions of predictable potency are unfounded.^[9] These data and guidelines contradict influencer claims that all forms of bioidentical hormone therapy are inherently safer or more effective than conventional, FDA‑approved hormone therapy, particularly when products are unregulated and individually compounded.

Mainstream view

Mainstream medical and scientific consensus differentiates between FDA/EMA‑approved bioidentical hormone formulations and custom‑compounded bioidentical hormone therapy. Approved preparations using estradiol and micronized progesterone are viewed as standard menopausal hormone therapy options with demonstrated short‑ to medium‑term efficacy for vasomotor symptom relief and established endometrial safety when appropriately dosed; their overall risk–benefit profile is considered broadly comparable to that of non‑bioidentical estrogen–progestin regimens and they are endorsed in guideline statements as acceptable first‑line therapy for many symptomatic women.^[15][16] In contrast, custom‑compounded bioidentical hormone therapy (often promoted by influencers) is not recommended for routine use because high-quality evidence on long‑term safety, cancer and cardiovascular risks, and comparative effectiveness is insufficient, and because compounded products lack rigorous regulatory oversight, standardized dosing, and manufacturing quality control.^[12][16] Mainstream guidance therefore supports regulated bioidentical hormone therapy within evidence‑based indications while cautioning against the routine use or marketing of compounded bioidentical hormone therapy as safer or superior. Influencer claims that “bioidentical hormone replacement therapy” in general is uniquely safe, more natural, or clearly superior to conventional hormone therapy are not supported by current evidence and guidelines. Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).

In their own wordsView sourceArchived copy

“Bioidentical Hormone Replacement Therapy”

Rule: Cal Naturopathic Practice – hormone prescribing authority (summarized at CalND Scope of Practice)

Jesse Pierce is not licensed or approved by State Board of Naturopathic Medicine to advertise Say Goodbye to Hormonal Imbalance as within their scope of practice.

Say Goodbye to Hormonal Imbalance

Supports

The broad marketing-style claim “say goodbye to hormonal imbalance” is not directly addressed by the provided index papers; they largely focus on hypertension, clinical nutrition, and specific non-endocrine conditions, so they do not provide supporting evidence for a universal cure or elimination of hormonal imbalance. ^[3][9][11] High-quality endocrine references and clinical practice guidelines (e. ^[2][12][13] g. , Endocrine Society guidelines on hypopituitarism, menopause, thyroid disease, diabetes, PCOS) consistently show that many specific hormonal imbalances can be effectively treated, controlled, or put into biochemical remission with hormone replacement, suppressive therapy, surgery, or other targeted interventions, often normalizing lab values and markedly improving symptoms. Some endocrine disorders (e. ^[10] g. , certain benign hormone-producing adenomas, some forms of hyperthyroidism after radioiodine or surgery, some pituitary or adrenal tumors) may be functionally cured when the underlying cause is removed or ablated, leading to long-term normalization of hormone levels. Evidence-based reviews on conditions such as PCOS and menopause show that symptoms driven by hormonal imbalance (e. ^[1] g. , hyperandrogenism, vasomotor symptoms) can often be substantially reduced or controlled with guideline-directed therapy and lifestyle modification, so from a practical symptom-control perspective, many patients can experience what feels like “saying goodbye” to many manifestations of imbalance, even if ongoing management is required.

Contradicts

The provided index papers relate to hypertension management, parenteral nutrition, inflammatory bowel disease nutrition, and specific oncology or hepatology trials; they do not show that hormonal imbalance as a general category can be permanently eliminated. ^[1][3][9] Authoritative endocrine sources describe hormonal imbalance as a broad umbrella term for many chronic endocrine disorders (thyroid disease, diabetes, PCOS, adrenal insufficiency, hypopituitarism, etc. ^[10][11] ), many of which require lifelong monitoring and, frequently, lifelong replacement or suppressive therapy rather than a one-time cure. Clinical guidelines on hypopituitarism and other endocrine deficiencies explicitly recommend lifelong hormone replacement and long-term monitoring to avoid under- or over-replacement, directly contradicting the implication that one can simply “say goodbye” to hormonal imbalance in a permanent, no-maintenance way. ^[2][12] Regulatory and guideline discussions of endocrine disorders note that while treatment “controls” many conditions and allows near-normal life, patients usually remain classified as having an endocrine disorder, with risk of relapse or need for dose adjustment, meaning the underlying propensity to imbalance remains. ^[13] Many hormonal fluctuations are physiologic (puberty, menstrual cycle, pregnancy, menopause, aging) and cannot or should not be eliminated; marketing the idea of fully eliminating “hormonal imbalance” oversimplifies complex, often lifelong physiology and pathology. There is no high-quality evidence that a single product, protocol, or general approach can permanently prevent or abolish all forms of hormonal imbalance across conditions and life stages.

Mainstream view

Mainstream endocrinology views “hormonal imbalance” not as a single disease that can be universally cured but as a heterogeneous set of endocrine disorders and normal life-stage changes. ^[10] For specific endocrine diseases, there are strong, guideline-based treatments that can normalize hormone levels and alleviate symptoms, and in some cases cure is possible when the underlying cause is eliminated. ^{[9][11][12][13]} However, many common hormonal disorders (thyroid disease, type 1 diabetes, many pituitary deficiencies, primary adrenal insufficiency, some cases of PCOS, menopause-related symptoms) are managed chronically with medication, monitoring, and lifestyle measures rather than fully eradicated. Patients can often achieve excellent symptom control and near-normal quality of life, but ongoing follow-up and treatment adjustments are standard of care. Mainstream medicine therefore supports evidence-based management of specific hormonal conditions, not the blanket promise that one can definitively “say goodbye” to hormonal imbalance in a permanent, one-size-fits-all manner. ^[1]

In their own wordsView sourceArchived copy

“Say Goodbye to Hormonal Imbalance”

Rule: Cal Naturopathic Practice – diagnosis and hormone prescribing (summarized at CalND Scope of Practice)

Jesse Pierce is not licensed or approved by State Board of Naturopathic Medicine to diagnose, treat, or cure Treating 'Hormonal Imbalance' and offering 'Bioidentical Hormone Replacement Therapy' (endocrine disorder)..

Treating 'Hormonal Imbalance' and offering 'Bioidentical Hormone Replacement Therapy' (endocrine disorder).

Supports

The core idea of bioidentical menopausal hormone therapy is to use hormones structurally identical to endogenous estradiol (E2) and progesterone (P4), often delivered as estradiol plus micronized progesterone. High-quality randomized trials show that FDA‑approved oral bioidentical estradiol/progesterone combinations (such as TX‑001HR/Bijuva) are effective for relief of menopausal vasomotor symptoms, with breast and bleeding outcomes broadly similar to conventional hormone therapy over 12 months.^[15] These RCTs demonstrate adequate endometrial protection when 1 mg E2 is combined with 100 mg P4, with endometrial hyperplasia rates below 1%, meeting regulatory safety criteria.^[15] Systematic and randomized data on micronized progesterone show it can effectively oppose estrogen’s proliferative effects on the endometrium at appropriate doses, reducing glandular proliferation and protecting against hyperplasia.^[3][13][15] Narrative and guideline-level reviews indicate that approved bioidentical E2/P4 regimens provide standardized pharmacokinetics and a risk–benefit profile comparable to other estrogen–progestin therapies when used at evidence-based doses, and can be considered an effective option for symptomatic menopausal women.^[14][15]

Contradicts

The strongest contradictions apply not to regulated bioidentical products but to custom-compounded bioidentical hormone therapy as promoted by many influencers. Major professional guidance (e.g., ACOG) explicitly notes that evidence to support marketing claims of superior safety and effectiveness of compounded bioidentical menopausal hormone therapy is lacking and calls for high-quality randomized trials comparing custom‑compounded products with FDA‑approved hormone therapy.^[12] The 2022 position statement of the North American Menopause Society similarly highlights a dearth of safety and efficacy data and little or no robust pharmacokinetic evidence for compounded bioidentical hormone therapy, pointing out safety concerns including inconsistent dosing, impurities, lack of sterility, and absence of standardized risk labeling; it recommends compounded products only when women cannot tolerate any approved formulation or require a non‑available dose/formulation.^[16] A randomized pharmacokinetic trial comparing commonly used doses of compounded “Bi‑est” estrogen cream plus compounded progesterone with a standard estradiol patch plus micronized progesterone showed that compounded regimens produced substantially lower and more variable estradiol exposure than the patch, indicating that typical compounded doses may not be bioequivalent and that assumptions of predictable potency are unfounded.^[9] These data and guidelines contradict influencer claims that all forms of bioidentical hormone therapy are inherently safer or more effective than conventional, FDA‑approved hormone therapy, particularly when products are unregulated and individually compounded.

Mainstream view

Mainstream medical and scientific consensus differentiates between FDA/EMA‑approved bioidentical hormone formulations and custom‑compounded bioidentical hormone therapy. Approved preparations using estradiol and micronized progesterone are viewed as standard menopausal hormone therapy options with demonstrated short‑ to medium‑term efficacy for vasomotor symptom relief and established endometrial safety when appropriately dosed; their overall risk–benefit profile is considered broadly comparable to that of non‑bioidentical estrogen–progestin regimens and they are endorsed in guideline statements as acceptable first‑line therapy for many symptomatic women.^[15][16] In contrast, custom‑compounded bioidentical hormone therapy (often promoted by influencers) is not recommended for routine use because high-quality evidence on long‑term safety, cancer and cardiovascular risks, and comparative effectiveness is insufficient, and because compounded products lack rigorous regulatory oversight, standardized dosing, and manufacturing quality control.^[12][16] Mainstream guidance therefore supports regulated bioidentical hormone therapy within evidence‑based indications while cautioning against the routine use or marketing of compounded bioidentical hormone therapy as safer or superior. Influencer claims that “bioidentical hormone replacement therapy” in general is uniquely safe, more natural, or clearly superior to conventional hormone therapy are not supported by current evidence and guidelines. Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).

In their own wordsView sourceArchived copy

“Bioidentical Hormone Replacement Therapy”

Rule: Cal Naturopathic Practice – diagnosis and hormone prescribing (summarized at CalND Scope of Practice)

Jesse Pierce is not licensed or approved by State Board of Naturopathic Medicine to diagnose, treat, or cure Bioidentical Hormone Replacement Therapy (HRT).

Bioidentical Hormone Replacement Therapy (HRT)

Supports

The core idea of bioidentical menopausal hormone therapy is to use hormones structurally identical to endogenous estradiol (E2) and progesterone (P4), often delivered as estradiol plus micronized progesterone. High-quality randomized trials show that FDA‑approved oral bioidentical estradiol/progesterone combinations (such as TX‑001HR/Bijuva) are effective for relief of menopausal vasomotor symptoms, with breast and bleeding outcomes broadly similar to conventional hormone therapy over 12 months.^[15] These RCTs demonstrate adequate endometrial protection when 1 mg E2 is combined with 100 mg P4, with endometrial hyperplasia rates below 1%, meeting regulatory safety criteria.^[15] Systematic and randomized data on micronized progesterone show it can effectively oppose estrogen’s proliferative effects on the endometrium at appropriate doses, reducing glandular proliferation and protecting against hyperplasia.^[3][13][15] Narrative and guideline-level reviews indicate that approved bioidentical E2/P4 regimens provide standardized pharmacokinetics and a risk–benefit profile comparable to other estrogen–progestin therapies when used at evidence-based doses, and can be considered an effective option for symptomatic menopausal women.^[14][15]

Contradicts

The strongest contradictions apply not to regulated bioidentical products but to custom-compounded bioidentical hormone therapy as promoted by many influencers. Major professional guidance (e.g., ACOG) explicitly notes that evidence to support marketing claims of superior safety and effectiveness of compounded bioidentical menopausal hormone therapy is lacking and calls for high-quality randomized trials comparing custom‑compounded products with FDA‑approved hormone therapy.^[12] The 2022 position statement of the North American Menopause Society similarly highlights a dearth of safety and efficacy data and little or no robust pharmacokinetic evidence for compounded bioidentical hormone therapy, pointing out safety concerns including inconsistent dosing, impurities, lack of sterility, and absence of standardized risk labeling; it recommends compounded products only when women cannot tolerate any approved formulation or require a non‑available dose/formulation.^[16] A randomized pharmacokinetic trial comparing commonly used doses of compounded “Bi‑est” estrogen cream plus compounded progesterone with a standard estradiol patch plus micronized progesterone showed that compounded regimens produced substantially lower and more variable estradiol exposure than the patch, indicating that typical compounded doses may not be bioequivalent and that assumptions of predictable potency are unfounded.^[9] These data and guidelines contradict influencer claims that all forms of bioidentical hormone therapy are inherently safer or more effective than conventional, FDA‑approved hormone therapy, particularly when products are unregulated and individually compounded.

Mainstream view

Mainstream medical and scientific consensus differentiates between FDA/EMA‑approved bioidentical hormone formulations and custom‑compounded bioidentical hormone therapy. Approved preparations using estradiol and micronized progesterone are viewed as standard menopausal hormone therapy options with demonstrated short‑ to medium‑term efficacy for vasomotor symptom relief and established endometrial safety when appropriately dosed; their overall risk–benefit profile is considered broadly comparable to that of non‑bioidentical estrogen–progestin regimens and they are endorsed in guideline statements as acceptable first‑line therapy for many symptomatic women.^[15][16] In contrast, custom‑compounded bioidentical hormone therapy (often promoted by influencers) is not recommended for routine use because high-quality evidence on long‑term safety, cancer and cardiovascular risks, and comparative effectiveness is insufficient, and because compounded products lack rigorous regulatory oversight, standardized dosing, and manufacturing quality control.^[12][16] Mainstream guidance therefore supports regulated bioidentical hormone therapy within evidence‑based indications while cautioning against the routine use or marketing of compounded bioidentical hormone therapy as safer or superior. Influencer claims that “bioidentical hormone replacement therapy” in general is uniquely safe, more natural, or clearly superior to conventional hormone therapy are not supported by current evidence and guidelines. Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).

In their own wordsView sourceArchived copy

“Bioidentical Hormone Replacement Therapy”

Rule: Cal Naturopathic Practice – hormone prescribing authority (summarized at CalND Scope of Practice)

Jesse Pierce is not licensed or approved by State Board of Naturopathic Medicine to advertise support individuals facing chronic, multifactorial health conditions as within their scope of practice.

support individuals facing chronic, multifactorial health conditions

Supports

The claim is extremely broad and vague, but at its core it implies that interventions can meaningfully support individuals living with chronic, multifactorial health conditions, such as multimorbidity or complex chronic disease. Systematic reviews of complex and comprehensive care programs for people with multiple chronic conditions or frailty generally support that some structured, multifactorial models of care (for example comprehensive geriatric assessment, patient‑centred medical homes, and community case‑management/care‑planning programs) can improve selected outcomes such as prescribing quality, risk‑factor control, and sometimes hospital use and functional status.^{[6][2][8][14]} High‑quality systematic reviews and meta‑analyses of telehealth and digital health interventions show that multifactorial, often behaviour‑change–based programs can support self‑management and improve lifestyle risk factors (diet quality, fruit and vegetable intake, sodium reduction) and some clinical markers in adults with chronic disease.^{[3][7][9][1][10][21]} For dietary interventions delivered by digital health to adults with diet‑related chronic conditions, a recent systematic review and meta‑analysis found modest but significant improvements in diet and some clinical outcomes, indicating these tools can support management of chronic conditions.^[1][4] Telehealth methods delivering multifactorial dietary interventions in chronic disease produce moderate improvements in dietary adherence and modest improvements in diet quality and sodium intake, again supporting their role in chronic disease management.^{[3][7][9][11]} Systematic metareviews of telehealth interventions for self‑management of long‑term conditions (diabetes, heart failure, asthma, COPD, cancer) report that more intensive and multifaceted interventions are associated with greater improvements in disease control and self‑management outcomes, supporting the idea that complex, multi‑component interventions can help people with multifactorial chronic conditions.^[13] Overviews of eHealth interventions for chronic diseases show consistent improvements in self‑care behaviours and related clinical indicators (such as HbA1c, blood pressure, hospitalization, cholesterol, weight), indicating that such interventions can support individuals living with chronic conditions.^[10] Systematic reviews focusing on multimorbidity and multiple long‑term conditions show that complex interventions incorporating behaviour‑change techniques like goal setting, monitoring, problem solving, and information about consequences are associated with improved outcomes in many trials, which supports the concept that structured support can benefit people with multifactorial chronic health problems.^[6][5][16]

Contradicts

Because the influencer’s claim is very general (“support individuals facing chronic, multifactorial health conditions”) and does not specify mechanism, intensity, or outcomes, it goes beyond what the evidence can firmly state. Systematic reviews of complex interventions for multimorbidity and multiple long‑term conditions consistently emphasize that overall effects are mixed and often modest, and that it is difficult to improve broad outcomes in this population; benefits tend to be limited to specific risk factors or functional difficulties rather than general cure or large improvements.^{[6][2][8][14]} Reviews of complex care programs for older adults with ongoing health and social care needs find that although some interventions trend towards fewer hospital admissions or long‑term care use, meta‑analyses frequently show non‑significant effects and considerable heterogeneity, indicating that not all complex interventions reliably “support” patients in a strong, consistent way.^[14] Systematic assessments of holistic assessment‑based complex interventions for people with multiple long‑term conditions report inconsistent evidence across settings and outcomes, with good evidence of benefit for only a few models (such as specific comprehensive geriatric assessment programs and patient‑centred medical homes) and no good evidence for generic holistic‑assessment interventions.^[2] Telehealth and digital dietary interventions for chronic disease yield only modest improvements in diet and clinical outcomes, with some important parameters (such as total energy and fat intake) not significantly changed; this suggests that while these interventions offer support, their impact is limited and they are not broadly transformative.^[3][7][1] Overviews of eHealth and mHealth interventions highlight substantial variability in user engagement, definitions of engagement, study quality, and outcome reporting, with many studies non‑randomized or pilot‑scale and engagement often declining over time, which weakens strong claims that such approaches consistently support all individuals with complex chronic conditions.^[10][19] Evidence on complex primary‑care interventions for multimorbidity is still limited, with few economic analyses and many context‑dependent results, leading reviewers to conclude that there is no one‑size‑fits‑all solution and that targeted, carefully designed interventions are needed rather than broad assurances that any support strategy will be effective.^[6][8][22]

Mainstream view

The mainstream medical and scientific view is ^{[14][15][16][17][2][3]}

In their own wordsView sourceArchived copy

“support individuals facing chronic, multifactorial health conditions”

Rule: Cal Naturopathic Practice – diagnosis and treatment modalities (summarized at CalND Scope of Practice)

Jesse Pierce is not licensed or approved by State Board of Naturopathic Medicine to advertise Heavy Metals Like Lead, Mercury, and Aluminum Affecting Your Health as within their scope of practice.

Heavy Metals Like Lead, Mercury, and Aluminum Affecting Your Health

Supports

There is strong, high‑quality evidence that heavy metals such as lead and mercury adversely affect human health, even at relatively low levels of exposure. ^[24][25] Major public health bodies state that lead exposure has no safe threshold and can damage virtually all organ systems, with particular effects on the central nervous system, cardiovascular system, kidneys, and hematologic parameters in both children and adults. Lead exposure in children is linked to permanent neurocognitive impairment and developmental problems, and in adults to hypertension, cardiovascular disease, kidney damage, and other chronic outcomes. These positions are based on extensive epidemiologic data and are reflected in global guidance documents and fact sheets from international health agencies. Mercury (especially methylmercury and inorganic mercury vapor) is well established as a neurotoxin that can cause sensory disturbances, tremors, cognitive impairment, coordination problems, and serious developmental neurotoxicity when exposure occurs in utero or early life. ^[22] Chronic mercury exposure has also been associated with cardiovascular effects such as endothelial dysfunction and hypertension in mechanistic and epidemiologic studies. Systematic and narrative toxicology reviews conclude that mercury can affect the nervous, renal, immune, and cardiovascular systems at exposure levels previously thought to be safe. Aluminum is less clearly established as a human neurotoxin at typical environmental or dietary exposures, but there is evidence that at high exposures (e. g. , in occupational settings or in dialysis patients) aluminum can accumulate in bone and brain, leading to bone disease and neurotoxicity, including dialysis dementia. Toxicology and mechanistic reviews note that aluminum can interfere with neuronal function, and that aluminum neurotoxicity produces changes similar to degenerative lesions observed in Alzheimer’s disease, although causality at usual exposure levels remains uncertain. A systematic review and meta‑analysis of long‑term occupational exposure to lead, mercury, and aluminum and risk of dementia reports that chronic aluminum exposure is associated with an increased risk of dementia, whereas evidence for lead and mercury is inconclusive, consistent with aluminum having potential neurotoxic effects under specific exposure circumstances. Another systematic review and meta‑analysis finds associations between exposure to heavy metals including lead and mercury and neurodevelopmental disorders such as autism spectrum disorder in children, supporting the concept that heavy metals can adversely affect child neurodevelopment, although causality and specific pathways remain complex. A recent comprehensive toxicology review details health hazards of aluminum, lead, mercury, and other metals in drinking water, describing multi‑system effects including neurotoxicity, nephrotoxicity, hematologic effects, and oxidative stress, reinforcing that these metals can affect health when exposure exceeds protective limits. ^[23] contradicts

Mainstream view

Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim). ^{[22][23][24][25]}

In their own wordsView sourceArchived copy

“Heavy Metals Like Lead, Mercury, and Aluminum Affecting Your Health”

Jesse Pierce is not licensed or approved by State Board of Naturopathic Medicine to advertise MINERAL IMBALANCES: WHAT YOU SHOULD KNOW as within their scope of practice.

MINERAL IMBALANCES: WHAT YOU SHOULD KNOW

No specific health claims of theirs were cross-checked against the literature.

In their own wordsView sourceArchived copy

“MINERAL IMBALANCES: WHAT YOU SHOULD KNOW”

Rule: Cal Naturopathic Practice – treatment with nutrients (summarized at CalND Scope of Practice)

Jesse Pierce is not licensed or approved by State Board of Naturopathic Medicine to advertise Acid Reflux: Natural Relief and Prevention as within their scope of practice.

Acid Reflux: Natural Relief and Prevention

No specific health claims of theirs were cross-checked against the literature.

In their own wordsView sourceArchived copy

“Acid Reflux: Natural Relief and Prevention”

Rule: Cal Naturopathic Practice – diagnosis and naturopathic treatment (summarized at CalND Scope of Practice)